Sinovac FY25 H1 swings to net loss of $21.7 million; net sales rise 1.21% to $130.3 million
PUBT · 05/08 21:00
Share
Listen to the news
- Sinovac Biotech posts net loss attributable to common shareholders of USD 21.7 million, or USD 0.30 per diluted share.
- Net sales edge up 1.21% to USD 130.3 million.
- Gross margin climbs 8.5 percentage points to 62.5%.
- Loss on disposal and impairment widens to USD 69.9 million, including USD 68.1 million tied to IPR&D and goodwill from a rabies-vaccine subsidiary acquisition.
- CEO Weidong Yin flags growth in Latin America and Southeast Asia offsetting softer demand in Chinese Mainland, citing wins in Chile’s influenza vaccine tender for 2025-26.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sinovac Biotech Ltd. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260508098846) on May 08, 2026, and is solely responsible for the information contained therein.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending